Rosewood, Motilal Oswal-backed Symbiotec Pharmalab files draft papers to raise Rs 2,180 crore via IPO

Symbiotec Pharmalab IPO News

Madhya Pradesh-based pharmaceutical and biotechnology company Symbiotec Pharmalab, which is backed by Rosewood Investments, and Motilal Oswal, has tapped capital markets by filing Draft Red Herring Prospectus (DRHP) with the SEBI on December 19 to raise Rs 2,180 crore via initial public offering (IPO).

The company has proposed to mop up Rs 150 crore via issuance of fresh shares, while existing shareholders will be selling up to Rs 2,030 crore worth shares via offer-for-sale.

Promoter Satwani Holdings, and investors - Rosewood Investments, and India Business Excellence Fund – III will be selling shareholders in the offer-for-sale.

Ahead of its filing Red Herring Prospectus for the IPO launch, the company may consider raising funds up to Rs 30 crore via pre-IPO placement, which is a part of fresh issue.

Symbiotec Pharmalab will utilise Rs 112.5 crore of fresh issue proceeds for repaying partial debt, and the remainder funds for general corporate purposes, while the offer-for-sale money will be received by the selling shareholders.

As of June 2025, the total fund-based outstanding borrowings (on a standalone basis) amounted to Rs 284.1 crore, said the company in its DRHP.

With two operational API manufacturing facilities with a maximum chemical synthesis capacity of 584.67 metric tonnes and fermentation capacity of 300 kilolitres, Symbiotec claims a global leadership position in corticosteroid and steroidal-hormone active pharmaceutical ingredients (APIs), with a global volume market share of 36.2 percent in corticosteroid and 44.2 percent in steroidal-hormone APIs.

Click Here To Read All IPO News

Currently, promoters hold 26.91 percent stake in the company that competes with four Indian listed peers Concord Biotech, Divi's Laboratories, Cohance Lifesciences, and Laurus Labs.

Rosewood Investments, advised by InvAscent, is the largest investor in Symbiotec with 37.19 percent stake, followed by Motilal Oswal's India Business Excellence Fund – III (24.47 percent stake).

Actis, and Franklin Templeton, and late Rakesh Jhunjhunwala were the past investors in the company.

On the financial front, Symbiotec has reported profit of Rs 29.9 crore on revenue of Rs 203.1 crore for the quarter ended June 2025. Profit in the financial year 2024-25 stood at Rs 96.8 crore, falling 3.3 percent compared to Rs 100 crore in previous year, however, revenue during the same fiscals increased 5 percent to Rs 751.6 crore, up from Rs 716.2 crore.

Symbiotec Pharmalab has appointed four merchant bankers - JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India) - for managing its IPO.